Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment (Antibiotics, Blood products, Colony stimulating factors, Bone marrow transplant, Stem cell transplant, Blood/platelet transfusions, Pipeline products) - Growth, Future Prospects and Competitive Landscape, 2025 - 2033

17 Nov 2022 Format PDF icon PPT icon XLS icon Request Sample

The incidence of radiation toxicity is on a rise with increase in treatment and diagnosis of various diseases using radiation therapy and nuclear medicine, thus driving the overall market growth. Cancer treatment predominantly utilizes radiation therapy to treat tumours and cancerous cells. Growing prevalence of cancer thus increases the rate of radiation therapy indicating growing risk of radiation toxicity. The American Cancer Society projected 1,735,350 new cancer cases to occur in US in the year 2018 and further estimated 609,640 deaths to occur in the similar year. Based on various research studies, around 60% patients undergo radiation therapy of which 5-10% experience radiation toxicity. However, the high cost of radiation therapy would lead to lesser patients opting for it particularly in low and middle-income regions. This factor could reduce the rate of radiation toxicities thus restraining the market growth.

The treatment options for radiation toxicity comprise bone marrow transplant, blood/ platelet transfusion (used to treat anaemia conditions), and antibiotics (prescribed to diminish the threats of various infections). Aeolus pharmaceuticals is currently developing (Phase I) a molecule named AEOL-10150 for the treatment of acute radiation syndrome.

Radiation toxicity can occur due to either intentional exposure to radiations or accidental exposure such as nuclear power plant accidents. Providing first aid to radiation victims may also increase the risk of exposure of radiation to the rescue personnel. The rising number of respective patients has attracted many pharmaceutical industries to invest in this market and carry out various research activities in development of suitable therapies.

North America predominates the global radiation toxicity treatment market with market share of 38% in 2024, which is followed by Europe. The dominance is attributed to the growing awareness on available treatment options. Asia Pacific is also a potential market owing to its developing healthcare infrastructure, rising awareness on healthcare and growing cancer prevalence.The key industrial players enjoying supremacy in this market are Aggrebind, Inc., Altacrete, Caterpillar Inc., Global Road Technology, Graymont Limited, Snf Holding Company Inc., Soilworks, Wirtgen Group and Others.

Historical & Forecast Period

This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2023-2033
Base Year 2024
Forecast Period  2025-2033
Historical Year  2023
Unit  USD Million
Segmentation
Treatment
  • Antibiotics
  • Blood products
  • Colony stimulating factors
  • Bone marrow transplant
  • Stem cell transplant
  • Blood/platelet transfusions
  • Pipeline products
    •     Tempol ( Phase II)
    •     AEOL-10150 (Phase I)

 Region Segment (2023-2033; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market?
  • Which is the largest regional market for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market worldwide?
Choose Licence Type
$4500
$6500
$9000
Why Acute
View Other Reports